MX2018008448A - Reducción de especies de alto peso molecular, especies con carga ácida, y fragmentos en una composición de anticuerpo monoclonal. - Google Patents

Reducción de especies de alto peso molecular, especies con carga ácida, y fragmentos en una composición de anticuerpo monoclonal.

Info

Publication number
MX2018008448A
MX2018008448A MX2018008448A MX2018008448A MX2018008448A MX 2018008448 A MX2018008448 A MX 2018008448A MX 2018008448 A MX2018008448 A MX 2018008448A MX 2018008448 A MX2018008448 A MX 2018008448A MX 2018008448 A MX2018008448 A MX 2018008448A
Authority
MX
Mexico
Prior art keywords
species
molecular weight
high molecular
level
monoclonal antibodies
Prior art date
Application number
MX2018008448A
Other languages
English (en)
Inventor
Santoro Marc
John Jose Kevin
Madabhushi Sri
Gangloff Scott
Original Assignee
Oncobiologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncobiologics Inc filed Critical Oncobiologics Inc
Publication of MX2018008448A publication Critical patent/MX2018008448A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M21/00—Bioreactors or fermenters specially adapted for specific uses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Las alteraciones en la alimentación de cultivo celular en biorreactor a una alimentación prolongada o continua después de un periodo inicial de no alimentación reducen el nivel de alto peso molecular, carga ácida, y las especies de fragmentos de anticuerpos monoclonales expresados en el cultivo, y mejora el nivel de las especies afucosiladas de los anticuerpos monoclonales expresados en el cultivo. Las infusiones de fucosa regulares después de un periodo inicial de no infusión de medio de alimentación reducen el nivel de especies afucosiladas de anticuerpos monoclonales expresados en el cultivo. La manipulación del cultivo celular puede utilizarse para modular el nivel de las especies de anticuerpos monoclonales.
MX2018008448A 2016-01-06 2017-01-05 Reducción de especies de alto peso molecular, especies con carga ácida, y fragmentos en una composición de anticuerpo monoclonal. MX2018008448A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662275386P 2016-01-06 2016-01-06
PCT/US2017/012362 WO2017120359A1 (en) 2016-01-06 2017-01-05 Reduction of high molecular weight species, acidic charge species, and fragments in a monoclonal antibody composition

Publications (1)

Publication Number Publication Date
MX2018008448A true MX2018008448A (es) 2019-05-30

Family

ID=57944514

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018008448A MX2018008448A (es) 2016-01-06 2017-01-05 Reducción de especies de alto peso molecular, especies con carga ácida, y fragmentos en una composición de anticuerpo monoclonal.

Country Status (8)

Country Link
US (1) US20190048070A1 (es)
EP (1) EP3400242A1 (es)
JP (1) JP2019500878A (es)
CN (1) CN109153717A (es)
AU (1) AU2017206012A1 (es)
CA (1) CA3010600A1 (es)
MX (1) MX2018008448A (es)
WO (1) WO2017120359A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015057910A1 (en) 2013-10-16 2015-04-23 Oncobiologics, Inc. Buffer formulations for enhanced antibody stability
WO2016118707A1 (en) 2015-01-21 2016-07-28 Oncobiologics, Inc. Modulation of charge variants in a monoclonal antibody composition
WO2017136433A1 (en) 2016-02-03 2017-08-10 Oncobiologics, Inc. Buffer formulations for enhanced antibody stability
SG11202009216YA (en) * 2018-03-26 2020-10-29 Amgen Inc Total afucosylated glycoforms of antibodies produced in cell culture
HUP1800376A2 (hu) * 2018-11-07 2020-05-28 Richter Gedeon Nyrt Sejttenyészetben elõállított rekombináns glikoprotein glikozilációs-mintázatának megváltoztatására szolgáló módszer

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0569525A1 (en) * 1991-02-01 1993-11-18 Coulter Corporation METHOD OF PRODUCING F(ab') 2? FRAGMENTS OF IMMUNOGLOBULINS
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
AR058140A1 (es) * 2005-10-24 2008-01-23 Wyeth Corp Metodo de produccion proteica utilizando compuestos anti-senescencia
EP2154244B1 (en) * 2007-04-26 2017-04-12 Chugai Seiyaku Kabushiki Kaisha Cell culture method using amino acid-enriched medium
WO2010141855A1 (en) * 2009-06-05 2010-12-09 Momenta Pharmaceuticals, Inc. Methods of modulating fucosylation of glycoproteins
US20130295613A1 (en) * 2010-12-28 2013-11-07 Chugai Seiyaku Kabushiki Kaisha Animal cell culturing method
CA2838695C (en) * 2011-07-01 2017-02-14 Amgen Inc. Mammalian cell culture
WO2013114164A1 (en) * 2012-01-30 2013-08-08 Dr. Reddy's Laboratories Limited Method for obtaining glycoprotein composition with increased afucosylation content
WO2013114165A1 (en) * 2012-01-30 2013-08-08 Dr Reddy's Laboratories Limited Process of obtaining glycoprotein composition with increased afucosylation content
NO2760138T3 (es) * 2012-10-01 2018-08-04
ES2633960T3 (es) * 2012-10-15 2017-09-26 Bristol-Myers Squibb Company Procesos de cultivo de células de mamífero para la producción de proteínas
EP2990485B1 (en) * 2013-04-25 2019-09-11 Kaneka Corporation Fd chain gene or l chain gene each capable of increasing secretion amount of fab-type antibody
WO2015140700A1 (en) * 2014-03-19 2015-09-24 Dr. Reddy's Laboratories Limited Cell culture process
CN105779394B (zh) * 2015-03-20 2020-03-24 广东东阳光药业有限公司 一种降低抗体酸性峰含量和改良抗体糖型的细胞培养方法

Also Published As

Publication number Publication date
EP3400242A1 (en) 2018-11-14
WO2017120359A1 (en) 2017-07-13
US20190048070A1 (en) 2019-02-14
JP2019500878A (ja) 2019-01-17
CA3010600A1 (en) 2017-07-13
CN109153717A (zh) 2019-01-04
AU2017206012A1 (en) 2018-07-26

Similar Documents

Publication Publication Date Title
MX2018008447A (es) Modulacion de especies afucosilados en una composicion de anticuerpo monoclonal.
MX2018008448A (es) Reducción de especies de alto peso molecular, especies con carga ácida, y fragmentos en una composición de anticuerpo monoclonal.
PH12017500918A1 (en) Antibodies against cd73 and uses thereof
PH12017501114A1 (en) Anti-c5 antibodies and methods of use
MX2018005468A (es) Terapia dirigida contra el cáncer.
GEP20237513B (en) Improved methods for enhancing antibody productivity in mammalian cell culture and minimizing aggregation during downstream, formulation processes and stable antibody formulations obtained thereof
MX2018006973A (es) Anticuerpos anti-cd73 humanizados.
SG10201903912XA (en) Delivery of biomolecules to immune cells
MX2017005344A (es) Composiciones y metodos para reforzar la eficacia de inmunoterapia celular adoptiva.
PH12018501282A1 (en) Anti-c5 antibodies and methods of use
NZ631197A (en) Anti sez6 antibodies and methods of use
NZ602220A (en) Antibodies with ph dependent antigen binding
WO2013063186A3 (en) Monoclonal antibodies and methods of use
MX2020013695A (es) Biorreactores de peque?o volumen con volumenes de trabajo sustancialmente constantes y sistemas y metodos relacionados.
EP4282881A3 (en) Antibodies against csf-1r
WO2015195556A8 (en) Blocking cd38 using anti-cd38 f(ab')2 to protect nk cells
IL276910A (en) Fully fucose-free glycoforms of antibodies are produced in cell culture
AU2016335217A8 (en) Antigen receptors and uses thereof
MX2015011781A (es) Medio de cultivo celular y metodos de produccion de anticuerpos.
IL269197A (en) Control of fully apocosylated antibody glycoforms produced in cell culture
MX2015010428A (es) Anticuerpos anti-her2 altamente galactosilados y sus usos.
MX2016016918A (es) Composicion oral de anticuerpos anti-tnf alfa.
IN2014MU01100A (es)
MY193535A (en) Cell culture methods
EP2491142A4 (en) GENERATING AN IMMUNE RESPONSE TO REDUCE THE RISK OF DEVELOPING BRUCELLOSIS